findmyKOL
Clinical trialNCT05708859RecruitingPhase 4Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

SponsorMatthew J. BudoffEnrollment120AtherosclerosisType II Diabetes
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Lundquist Institute for Biomedical Innovation at Harbor Ucla Medical Center (the Lundquist Institute)

    Torrance, California, United States

    Matthew J Budoff, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Jan 2024
Primary completion
31 Dec 2025
Completion
31 May 2026
Last update posted
15 Oct 2024
Registered enrollment
120
Registry id
NCT05708859
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.